Fluorometholone Drops

Name: Fluorometholone Drops

Description

Fluorometholone ophthalmic suspension, USP 0.1% is a sterile topical anti-inflammatory agent for ophthalmic use.

Chemical Name

Fluorometholone: 9-Fluoro-11β,17-dihydroxy-6α-methylpregna-1,4-diene-3,20-dione.

Contains

Active: fluorometholone 0.1%. Preservative: benzalkonium chloride 0.004%. Inactives: edetate disodium; polysorbate 80; polyvinyl alcohol 1.4%; purified water; sodium chloride; sodium phosphate, dibasic; sodium phosphate, monobasic; and sodium hydroxide to adjust pH. Fluorometholone suspension is formulated with a pH from 6.2 to 7.5. It has an osmolality range of 290-350 mOsm/kg.

Structural Formula

fluorometholone

Clinical pharmacology

Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.

There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.

Corticosteroids are capable of producing a rise in intraocular pressure. In clinical studies of documented steroid-responders, fluorometholone demonstrated a significantly longer average time to produce a rise in intraocular pressure than dexamethasone phosphate; however, in a small percentage of individuals, a significant rise in intraocular pressure occurred within one week. The ultimate magnitude of the rise was equivalent for both drugs.

Contraindications

Fluorometholone ophthalmic suspension 0.1% is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye, and fungal diseases of ocular structures. Fluorometholone ophthalmic suspension 0.1% is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.

How supplied

Fluorometholone ophthalmic suspension, USP 0.1% is supplied sterile in opaque white LDPE plastic bottles with white high impact polystyrene (HIPS) caps as follows:

5 mL in 10 mL bottle NDC 60758-880-05
10 mL in 15 mL bottle NDC 60758-880-10
15 mL in 15 mL bottle NDC 60758-880-15

Storage: Store at 2°-25°C (36°-77°F); protect from freezing. Store in an upright position.

Revised: 02/2013

© 2013 Allergan, Inc.
Irvine, CA 92612, U.S.A.
® mark owned by Allergan, Inc.
Made in the U.S.A.

71599PY11

PACIFIC
PHARMA®

NDC 60758-880-10

FLUOROMETHOLONE

ophthalmic
suspension,
USP 0.1%

10 mL

sterile

Rx only

FLUOROMETHOLONE 
fluorometholone solution/ drops
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:60758-880
Route of Administration OPHTHALMIC DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
fluorometholone (fluorometholone) fluorometholone 1 mg  in 1 mL
Inactive Ingredients
Ingredient Name Strength
benzalkonium chloride  
edetate disodium  
polysorbate 80  
polyvinyl alcohol  
water  
sodium chloride  
sodium phosphate, dibasic  
sodium phosphate, monobasic  
sodium hydroxide  
Packaging
# Item Code Package Description
1 NDC:60758-880-05 1 BOTTLE, DROPPER in 1 CARTON
1 5 mL in 1 BOTTLE, DROPPER
2 NDC:60758-880-10 1 BOTTLE, DROPPER in 1 CARTON
2 10 mL in 1 BOTTLE, DROPPER
3 NDC:60758-880-15 1 BOTTLE, DROPPER in 1 CARTON
3 15 mL in 1 BOTTLE, DROPPER
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA authorized generic NDA016851 10/31/1997
Labeler - Pacific Pharma, Inc. (877645267)
Establishment
Name Address ID/FEI Operations
Allergan, Inc. 362898611 MANUFACTURE(60758-880)
Establishment
Name Address ID/FEI Operations
Allergan Pharmaceuticals Ireland 219682291 MANUFACTURE(60758-880)
Revised: 04/2013   Pacific Pharma, Inc.
(web3)